AZD7442 IM + Placebo IM + AZD7442 IM + Placebo IM + AZD7442 IV + Placebo IV + AZD7442 IV + Placebo IV
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus Disease 2019 (COVID-19)
Conditions
Coronavirus Disease 2019 (COVID-19), Healthy Volunteer
Trial Timeline
Oct 9, 2021 → Jan 16, 2023
NCT ID
NCT05437289About AZD7442 IM + Placebo IM + AZD7442 IM + Placebo IM + AZD7442 IV + Placebo IV + AZD7442 IV + Placebo IV
AZD7442 IM + Placebo IM + AZD7442 IM + Placebo IM + AZD7442 IV + Placebo IV + AZD7442 IV + Placebo IV is a phase 1 stage product being developed by AstraZeneca for Coronavirus Disease 2019 (COVID-19). The current trial status is completed. This product is registered under clinical trial identifier NCT05437289. Target conditions include Coronavirus Disease 2019 (COVID-19), Healthy Volunteer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05437289 | Phase 1 | Completed |
Competing Products
20 competing products in Coronavirus Disease 2019 (COVID-19)